The New England journal of medicine, 2023-06, Vol.388 (23), p.2145-2158
- Mirza, Mansoor R.
- Chase, Dana M.
- Slomovitz, Brian M.
- dePont Christensen, René
- Novák, Zoltán
- Black, Destin
- Gilbert, Lucy
- Sharma, Sudarshan
- Valabrega, Giorgio
- Landrum, Lisa M.
- Hanker, Lars C.
- Stuckey, Ashley
- Boere, Ingrid
- Gold, Michael A.
- Auranen, Annika
- Pothuri, Bhavana
- Cibula, David
- McCourt, Carolyn
- Raspagliesi, Francesco
- Shahin, Mark S.
- Gill, Sarah E.
- Monk, Bradley J.
- Buscema, Joseph
- Herzog, Thomas J.
- Copeland, Larry J.
- Tian, Min
- He, Zangdong
- Stevens, Shadi
- Zografos, Eleftherios
- Coleman, Robert L.
- Powell, Matthew A.
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Mirza, Mansoor R.
- Chase, Dana M.
- Slomovitz, Brian M.
- dePont Christensen, René
- Novák, Zoltán
- Black, Destin
- Gilbert, Lucy
- Sharma, Sudarshan
- Valabrega, Giorgio
- Landrum, Lisa M.
- Hanker, Lars C.
- Stuckey, Ashley
- Boere, Ingrid
- Gold, Michael A.
- Auranen, Annika
- Pothuri, Bhavana
- Cibula, David
- McCourt, Carolyn
- Raspagliesi, Francesco
- Shahin, Mark S.
- Gill, Sarah E.
- Monk, Bradley J.
- Buscema, Joseph
- Herzog, Thomas J.
- Copeland, Larry J.
- Tian, Min
- He, Zangdong
- Stevens, Shadi
- Zografos, Eleftherios
- Coleman, Robert L.
- Powell, Matthew A.
- Titel
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
- Ist Teil von
- The New England journal of medicine, 2023-06, Vol.388 (23), p.2145-2158
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa2216334Titel-ID: cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_305435
- Format
- –
- Schlagworte
- Adverse events, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Humanized - administration & dosage, Antibodies, Monoclonal, Humanized - adverse effects, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, Cancer, Cancer therapies, Carboplatin, Carboplatin - administration & dosage, Carboplatin - adverse effects, Cell death, Chemotherapy, Cytotoxicity, DNA Mismatch Repair, dostarlimab, Double-Blind Method, Endometrial cancer, Endometrial Neoplasms - drug therapy, Endometrial Neoplasms - genetics, Endometrial Neoplasms - mortality, Endometrial Neoplasms - pathology, Endometrium, Female, General Medicine, Gynecologic Oncology, Gynecology, Hematology, Hematology/Oncology, Human health sciences, Humans, Hypothesis testing, Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors - administration & dosage, Immune Checkpoint Inhibitors - adverse effects, Immunotherapy, Medicine (all), Microsatellite Instability, Mismatch repair, Monoclonal antibodies, Neoplasm Recurrence, Local - drug therapy, Neoplasm Recurrence, Local - etiology, Obstetrics, Obstetrics/Gynecology, Oncologie, Oncology, Paclitaxel, Paclitaxel - administration & dosage, Paclitaxel - adverse effects, Patients, Placebos, Quality of life, Questionnaires, Sciences de la santé humaine, Solid tumors, Statistical analysis, Targeted cancer therapy, Treatments in Oncology, Tumors